Hims & Hers Trades 10% Above BofA's Raised $25 Target as Novo Nordisk Launches Direct Wegovy Sales

NEW YORK, April 16 —

BofA Securities raised its price target on Hims & Hers Health, Inc. (NYSE: HIMS) to $25 from $21 and kept a Neutral rating. The shares aren't waiting. HIMS trades near $27.50, lifted by reports that the FDA is reconsidering restrictions on compounded peptide treatments. That puts the stock roughly 10% above BofA's new target and about 15% above the $24 Wall Street consensus — a gap driven by a headline, not by a change in the company's earnings power.

Background

Hims & Hers shares jumped over the past week after reports that the FDA is reviewing rules governing compounded peptide therapies — a category that includes semaglutide preparations sold through telehealth platforms. MarketWatch reported that the stock surged as the U.S. moved forward with a plan to reassess popular peptides. TipRanks and Seeking Alpha attributed the extended rally to public comments from Health and Human Services Secretary Robert F. Kennedy Jr., who signaled a looser stance on peptide restrictions.

The compounding question is central to the HIMS story. The company built a fast-growing GLP-1 franchise on compounded semaglutide, priced well below branded Wegovy and Zepbound. When the FDA previously declared the semaglutide shortage resolved, compounded supply faced tighter limits. A review that reopens a regulatory path for compounded peptides would, in theory, restore a portion of that runway. But a review is not a rule change. No new guidance has been published.

Then came the competitive shot. Novo Nordisk, the maker of Wegovy and Ozempic, announced its first direct-to-consumer Wegovy subscription in the same news cycle. The program puts branded GLP-1 on the same distribution model HIMS popularized — cutting out the pharmacy and telehealth middle layer in favor of a Novo-owned channel. Hims & Hers has not issued a public response to the Novo launch, according to its investor relations page.

Analyst View

Wall Street is more cautious than the stock price suggests. BofA raised its target to $25 from $21 but kept a Neutral rating, calling the increase a recalibration of multiple assumptions rather than a thesis change. The new target still sits below the current share price. The $24 consensus, per compiled analyst data on Yahoo Finance, implies a roughly 12.7% decline from the April 16 quote of $27.50.

A Seeking Alpha contributor argued on April 15 that EBITDA multiples on HIMS have compressed enough to matter once the "GLP-1 drama" fades. That bull case depends on two things: the compounding path staying open and branded competition remaining indirect. BofA's note and the consensus target say the sell-side isn't underwriting that outcome at current prices.

Earnings have been uneven. HIMS beat the quarterly EPS estimate in three of the past four reports. The most recent quarter: $0.20 actual versus $0.12 consensus, a roughly 66% beat. The quarter before: $0.17 versus $0.16. Two quarters back, the company missed by roughly 39%, reporting $0.06 against a $0.10 estimate. Marketing spend, gross margin mix, and category expansion still swing results quarter to quarter — the hallmark of a business whose profitability hasn't stabilized.

What the Data Shows

The business itself is profitable and cash-generative. Trailing-twelve-month revenue hit $2.3bn, gross margin runs near 73.8%, and free cash flow reached roughly $111mn, per the company's most recent public filings. This is a real operating company, not a pre-revenue concept. At 19.4x forward earnings, the multiple sits in range with consumer digital health names that have already proved they can sustain profitability.

The problem isn't quality. It's price. At $27.50, HIMS trades roughly 10% above BofA's $25 target published this week and about 15% above the $24 Street consensus. For a Neutral-rated stock, the message from the latest analyst action is clear: fair value moved up, but not to where the tape has moved. Two separate developments now cut against the rally.

First, the FDA action is a review, not a rule. The stock reacted to the framing of a reassessment and to public commentary — not to a published guidance document or a final order. A review can conclude in multiple directions. Any widening of the compounding pathway would typically come with defined conditions.

Second, Novo Nordisk's direct-to-consumer Wegovy subscription replicates the distribution model that let HIMS sell compounded GLP-1 treatments at a discount to branded therapy. If branded GLP-1 is available directly from the manufacturer on a subscription, the price spread that justified compounded alternatives narrows. The competitive advantage shifts from price to service, brand, and adjacent prescribing. That is harder to underwrite at a premium to consensus than a pure price-arbitrage pitch.

Insider activity over the past 90 days, disclosed through Form 4 filings on SEC EDGAR, shows open-market sales by several named executives, including the Chief Operating Officer, Chief Financial Officer, and Chief Legal Officer. The sales may have been executed under pre-arranged 10b5-1 plans; Form 4 disclosures do not state motivation. The selling pattern is worth flagging alongside the current rally but does not by itself confirm a direction.

Risks

The bull case for owning HIMS above consensus rests on three bets: the FDA review durably reopens compounded peptide supply, branded competitors fail to take share through direct distribution, and the broader consumer health platform grows fast enough to justify a premium multiple even without GLP-1 revenue. Each is plausible. None is priced as uncertain in the current quote.

The bear case is concrete. If the FDA review concludes without widening the compounding pathway, the narrative behind the rally collapses. If Novo Nordisk's direct Wegovy offer gains traction, the addressable share of GLP-1 prescribing available to a telehealth compounder shrinks — regardless of the regulatory outcome. A stock stretched above Street targets while a major pharma competitor moves onto the same distribution channel is the kind of two-variable pressure that reprices quickly.

There is also a technical element. A stock trading 15% above consensus and 10% above the most recently raised sell-side target doesn't need a thesis-breaking catalyst to pull back. Fading momentum, index-driven selling, or a quiet regulatory update can do it. The cash-flow base is real enough to absorb that kind of move. It does not prevent it.

Outlook

Hims & Hers has a working business: $2.3bn in annual revenue, gross margins in the low seventies, and positive free cash flow. The question for the next two to three quarters is whether the regulatory and competitive picture settles in a way that justifies trading above a recently raised Neutral target. BofA's $25 mark and the $24 consensus say the sell-side, on balance, won't pay today's price. Novo Nordisk's direct Wegovy subscription is a credible challenge to the exact franchise that drove HIMS's last leg of growth — and it landed in the same news cycle as the peptide-review reports that fueled the rally. Investors considering a position at current levels should separate the regulatory signal from the regulatory outcome. The Novo launch is the more durable variable of the two.

Run the free Hims & Hers Health, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.